文献速递膀胱癌与上尿路尿路上皮癌

SPARE研究:选择性膀胱保留与根治性膀胱切除术的随机可行性研究的临床与患者报告结局

Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
PubMed 文献 · BJU Int · 2017-05-29

SPARE是一项多中心随机对照可行性研究,比较肌层浸润性膀胱癌(MIBC)患者接受新辅助化疗后根治性膀胱切除术(RC)与选择性膀胱保留(SBP)的结局。研究在30个月内仅招募45例(RC组25例,SBP组20例),招募未达预设目标,且对分配方案的不依从常见(RC组中6/25,24%接受了放疗)。按方案接受放疗者长期膀胱保留率为11/15(73%),两组总生存无显著差异。结论:在英国医疗体系内基于新辅助化疗反应随机分配RC与SBP不可行,因临床医生和患者对治疗有强烈偏好,且样本量少无法得出确切结论。

要点

  • SPARE研究30个月招募45例MIBC患者(RC组25例,SBP组20例),招募低于预设目标。
  • RC组中6/25(24%)未按分配接受RC而接受了放疗,不依从常见。
  • 按方案接受放疗者长期膀胱保留率为11/15(73%)。

核心结论

  • 基于新辅助化疗反应随机分配MIBC患者接受RC或SBP在英国医疗体系内不可行。
  • 临床医生和患者对治疗的强烈偏好影响了随机化意愿和治疗分配接受度。
  • 由于参与者少,无法就疾病和毒性结局得出确切结论。

研究设计与样本

  • SPARE为多中心随机对照试验,比较RC与SBP在MIBC患者中的可行性与结局。
  • 纳入分期T2-3 N0 M0、适合两种治疗策略并接受三周期新辅助化疗的患者。
  • 患者在第三周期新辅助化疗后膀胱镜检查前随机分配至RC或SBP。
  • 残留肿瘤≤T1者两组均接受第四周期新辅助化疗,SBP组随后接受根治性放疗,RC组接受RC;无反应者两组均在第三周期后立即行RC。
  • 可行性研究主要终点为入组率和分配治疗策略的依从性。

主要发现

  • 30个月内共招募45例患者(RC组25例,SBP组20例),招募困难且低于预设目标。
  • RC组25例中6例(24%)未按分配接受RC而接受了放疗。
  • 按方案接受放疗者长期膀胱保留率为11/15(73%)。
  • 两组总生存无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 招募困难且低于预设目标,30个月仅招募45例。
  • 对分配治疗策略的不依从常见,RC组25例中6例(24%)接受了放疗。
  • 由于参与者少,无法就疾病和毒性结局得出确切结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To test the feasibility of a randomised trial in muscle-invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy (RC) or selective bladder preservation (SBP), where definitive treatment [RC or radiotherapy (RT)] is determined by response to chemotherapy. PATIENTS AND METHODS: SPARE is a multicentre randomised controlled trial comparing RC and SBP in patients with MIBC staged T2-3 N0 M0, fit for both treatment strategies and receiving three cycles of neoadjuvant chemotherapy. Patients were randomised between RC and SBP before a cystoscopy after cycle three of neoadjuvant chemotherapy. Patients with ≤T1 residual tumour received a fourth cycle of neoadjuvant chemotherapy in both groups, followed by radical RT in the SBP group and RC in in the RC group; non-responders in both groups proceeded immediately to RC following cycle three. Feasibility study primary endpoints were accrual rate and compliance with assigned treatment strategy. The phase III trial was designed to demonstrate non-inferiority of SBP in terms of overall survival (OS) in patients whose tumours responded to neoadjuvant chemotherapy. Secondary endpoints included patient-reported quality of life, clinician assessed toxicity, loco-regional recurrence-free survival, and rate of salvage RC after SBP. RESULTS: Trial recruitment was challenging and below the predefined target with 45 patients recruited in 30 months (25 RC; 20 SBP). Non-compliance with assigned treatment strategy was frequent, six of the 25 patients (24%) randomised to RC received RT. Long-term bladder preservation rate was 11/15 (73%) in those who received RT per protocol. OS survival was not significantly different between groups. CONCLUSIONS: Randomising patients with MIBC between RC and SBP based on response to neoadjuvant chemotherapy was not feasible in the UK health system. Strong clinician and patient preferences for treatments impacted willingness to undergo randomisation and acceptance of treatment allocation. Due to the few participants, firm conclusions about disease and toxicity outcomes cannot be drawn.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017. PMID: 28453896. doi:10.1111/bju.13900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。